Unlock Exclusive Discounts & Flash Sales! Click Here to Join the Deals on Every Wednesday!
Epidermal growth factor receptor (EGFR) gene mutations have been reported to be present in non-small cell lung cancer (NSCLC) and are associated with tumor responsiveness to EGFR tyrosine kinase inhibitors, suggesting its usefulness as a biomarker. Since clinical samples contain both tumor cells and normal cells or genes, high-sensitivity assays to detect mutations are critical for clinical applications.